var data={"title":"Ocriplasmin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ocriplasmin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/525810?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ocriplasmin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ocriplasmin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15898399\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Jetrea</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24047896\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Jetrea</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15387675\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Ophthalmic Agent;</li>\n      <li>\n        Vitreolytic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032069\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Vitreomacular adhesion:</b> Intravitreal: 0.125 mg once (as a single dose to the affected eye)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032070\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032071\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032072\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15898400\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravitreal [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jetrea: 0.375 mg/0.3 mL (0.3 mL); 0.5 mg/0.2 mL (0.2 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032002\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032073\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For intravitreal injection only. Must be diluted prior to use. Adequate anesthesia and a broad-spectrum antimicrobial agent should be administered prior to the procedure. Administer the diluted solution to the mid-vitreous by inserting the injection needle 3.5 to 4 mm posterior to the limbus, aiming toward the center of the vitreous cavity and avoiding the horizontal meridian. Treatment of the second eye, if needed, is not recommended within 7 days of the first injection. Repeated administration to the same eye is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15387659\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Vitreomacular adhesion:</b> Treatment of symptomatic vitreomacular adhesion (VMA)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032001\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Jetrea: Brand name for ocriplasmin [U.S.] may be confused with Jetrex brand name for dextromethorphan, guaifenesin, bromhexine and chlorpheniramine maleate [India]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16027538\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">5% to 20%: Ophthalmic: Intraocular inflammation (7%), decreased visual acuity (6%), blurred vision, conjunctival hemorrhage, eye pain, macular degeneration, photopsia, retinal edema, visual impairment, vitreous opacity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;5%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hyperemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Chromatopsia (2%; primarily described as yellowish vision), abnormal electroretinogram (a- and b-wave amplitude decrease; &le;1%), anterior chamber inflammation, cataract, conjunctival hyperemia, decreased pupillary reflex, dry eye syndrome, eye discomfort, increased intraocular pressure, iritis, macular edema, metamorphopsia, photophobia, retinal degeneration, visual disturbance (contralateral eye), vitreous detachment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Nocturnal amblyopia, retinal detachment (pre-vitrectomy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032007\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to ocriplasmin or any component of the formulation; active or suspected ocular or periocular infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032008\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased vision: May cause decreased visual acuity as a result of condition progression with traction, which may require surgical intervention. Monitor visual acuity appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyschromatopsia: May cause dyschromatopsia, described as yellowish vision.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intravitreal injection: Intraocular inflammation, infection, hemorrhage, and/or increased intraocular pressure may result after intravitreal injection. In clinical trials, intraocular inflammation occurred at a higher rate with ocriplasmin when compared to placebo; intraocular inflammation events were typically mild and transient.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lens subluxation: Administration of higher than recommended doses may result in lens subluxation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Retinal breaks: After ocriplasmin administration, retinal detachment or retinal tear (with or without retinal detachment) may occur before, during, or after vitrectomy. Instruct patients to report symptoms suggestive of retinal detachment or endophthalmitis (eg, ocular pain, redness, photophobia, blurred/decreased vision).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Repeat administration in the same eye is not recommended. If the contralateral eye requires treatment, treatment is not recommended within 7 days of the initial injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16061141\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16061139\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=86876&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032003\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032004\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Systemic exposure following a single intravitreal injection is expected to be low.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032006\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ocriplasmin is present in breast milk. Systemic exposure following a single intravitreal injection is expected to be low. The manufacturer recommends that caution be exercised when administering ocriplasmin to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032086\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Following intravitreal injection, immediately monitor for elevation in intraocular pressure, signs of endophthalmitis, retinal detachment, or decreased vision.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032013\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ocriplasmin is a recombinant form of human plasmin that acts as a proteolytic within the vitreous body and vitreoretinal interface. Protein matrix components responsible for the vitreomacular adhesion (eg, laminin, fibronectin, and collagen) are lysed by ocriplasmin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16032015\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Detectable levels in systemic circulation are not expected after intravitreal injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Endogenous protein catabolism pathway; rapidly inactivated by protease inhibitor alpha-2-antiplasmin or alpha-2-macroglobulin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> &lt;3% of the administered dose is detected in vitreous fluid 24 hours after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570457\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Jetrea Intravitreal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375 mg/0.3 mL (0.3 mL): $3,555.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059513\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Jetrea (AE, AR, AT, BE, BR, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, IE, IL, IS, KR, LT, LU, MT, MY, NL, NO, PL, PT, RO, SE, SI, SK);</li>\n      <li>Zhetrea (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Jetrea (ocriplasmin) [prescribing information]. Iselin, NJ: ThromboGenics Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jetrea (ocriplasmin) [product monograph]. Mississauga, Ontario, Canada: Alcon Canada Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic Vitreolysis With Ocriplasmin for Vitreomacular Traction and Macular Holes. <i>N Engl J Med</i>. 2012;367(7):606-615.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ocriplasmin-drug-information/abstract-text/22894573/pubmed\" target=\"_blank\" id=\"22894573\">22894573</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 86876 Version 66.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F15898399\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F24047896\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F15387675\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F16032069\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F16032070\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16032071\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16032072\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F15898400\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F16032002\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F16032073\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F15387659\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16032001\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16027538\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F16032007\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F16032008\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16061141\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16061139\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F16032003\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16032004\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16032006\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F16032086\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16032013\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F16032015\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570457\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059513\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/86876|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ocriplasmin-patient-drug-information\" class=\"drug drug_patient\">Ocriplasmin: Patient drug information</a></li></ul></div></div>","javascript":null}